Form 4: Avidity Biosciences CEO Sarah Boyce Reports Stock Transactions Following PSU Vesting

Avidity Biosciences CEO Sarah Boyce reports acquisition and disposal of company stock related to the vesting of performance-based restricted stock units (PSUs) and subsequent sell-to-cover transactions.

Summary

• On September 19, 2024, Sarah Boyce, CEO of Avidity Biosciences, acquired 62,500 shares of common stock due to the vesting of performance-based restricted stock units (PSUs).
• These PSUs vested upon the achievement of a clinical event related to del-brax.
• Also on September 19, 2024, an additional 25,000 PSUs were earned and converted to time-based restricted stock units vesting on March 19, 2025.
• On September 23, 2024, Boyce sold 32,880 shares of common stock at a weighted-average price of $44.0001 to cover tax withholding obligations related to the PSU vesting.
• The sales occurred in multiple transactions with prices ranging from $44.00 to $44.02.
• Following these transactions, Boyce directly owns 234,663 shares of Avidity Biosciences common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The vesting of PSUs indicates achievement of performance goals, which is positive. The sale of shares is a standard tax-related transaction and not necessarily indicative of negative sentiment.

Positives

• The vesting of PSUs indicates the achievement of a company performance objective related to a clinical event for del-brax, which is a positive signal for the company's progress.

Negatives

• The sale of shares to cover tax obligations, while not discretionary, could be perceived negatively by some investors if they interpret it as a lack of confidence in the company's future prospects, although this is a standard practice.

Risks

• The future vesting of the remaining time-based restricted stock units is contingent upon Boyce's continued employment or service through March 19, 2025.

Future Outlook

An additional 25,000 time-based restricted stock units will vest on March 19, 2025, contingent upon the Reporting Person's continued employment or service through such date.

Industry Context

Form 4 filings are routine disclosures for company insiders and are closely watched by investors for insights into management's perspective on the company's stock. Sell-to-cover transactions are common and generally not indicative of a negative outlook.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard practice across the industry to manage tax obligations related to equity compensation.
• The weighted average price of $44.0001 is within a normal range for stock sales related to tax obligations.
• Comparable companies such as Alnylam Pharmaceuticals and Ionis Pharmaceuticals also see similar insider transactions related to equity compensation.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign of company performance.
• The sell-to-cover transaction has a minimal impact on stakeholders as it is a routine event.

Key Dates